Physician profile
James M Gilbert
NPI 1003802356
$5,814.47
in general payments reported to CMS, 2019-2025
29 companies · $200 in 2025
The $200 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $909 · 2020: $662 · 2021: $1,422 · 2022: $1,096 · 2023: $925 · 2024: $601 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,718 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,717.82 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,179.55 | 2019-2025 | Rexulti, Abilify Maintena |
| Abbvie INC. | $981.91 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $474.02 | 2019-2024 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $360.72 | 2020-2023 | |
| Corium, LLC | $343.39 | 2021-2023 | Azstarys |
| Avanir Pharmaceuticals, INC. | $327.02 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $321.13 | 2020-2022 | |
| Allergan, INC. | $284.99 | 2019-2020 | |
| Eisai INC. | $235.66 | 2020-2021 | |
| Acadia Pharmaceuticals INC | $218.68 | 2020-2023 | Nuplazid |
| Alkermes, INC. | $160.70 | 2021 | |
| Janssen Pharmaceuticals, INC | $128.95 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $122.19 | 2024 | Cobenfy |
| Vanda Pharmaceuticals INC. | $116.10 | 2019 | |
| Sunovion Pharmaceuticals INC. | $97.79 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $88.06 | 2019-2024 | Rexulti |
| Supernus Pharmaceuticals, INC. | $74.94 | 2023 | Qelbree |
| Neos Therapeutics, LP | $70.56 | 2019-2024 | Adzenys Xr-Odt |
| Shire North American Group INC | $62.31 | 2019 | |
| Arbor Pharmaceuticals, INC. | $24.55 | 2019 | |
| Bausch Health US, LLC | $21.68 | 2020 | |
| Ironshore Pharmaceuticals INC. | $19.39 | 2019 | |
| Idorsia Pharmaceuticals US INC | $17.84 | 2023 | Quviviq |
| Adlon Therapeutics L.P. | $16.02 | 2021 | |
| Neurocrine Biosciences, INC. | $14.67 | 2019 | |
| Genentech USA, INC. | $14.25 | 2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $14.20 | 2023 | Aplenzin |
| Amgen INC. | $12.34 | 2019 | |
| Amarin Pharma, INC. | $10.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Gilbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.